As of July 16, 2025, Genomic Vision SA (GV.PA) reports a ROE (Return on Equity) of 526.76%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Genomic Vision SA's ROE (Return on Equity)
Over recent years, Genomic Vision SA's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | 526.76% |
| 2021-12-31 | -162.80% |
| 2020-12-31 | -165.77% |
| 2019-12-31 | -142.80% |
| 2018-12-31 | -165.54% |
This slight upward trend highlights how Genomic Vision SA manages its efficiency in generating profits from shareholders' equity over time.
Comparing Genomic Vision SA's ROE (Return on Equity) to Peers
To better understand Genomic Vision SA's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Genomic Vision SA (GV.PA) | 526.76% |
| Aegirbio AB (AEGIR.ST) | 4108.47% |
| Xintela AB (XINT.ST) | 658.66% |
| Alligator Bioscience AB (ATORX.ST) | 179.11% |
| Inventiva SA (IVA.PA) | 172.73% |
| Pure Biologics SA (PUR.WA) | 148.18% |
Compared to its competitors, Genomic Vision SA's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.